Impact of the new rectal cancer definition on multimodality treatment and interhospital variability: Results from a nationwide cross-sectional study.
Sanne-Marije J A HazenTania C SluckinKarin HorsthuisDoenja M J LambregtsRegina G H Beets-TanRoel HompesTineke E BuffartCorrie A M MarijnenPieter J TanisMiranda Kustersnull nullPublished in: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2024)
By using the STO, 11% of the prior MDT-based diagnosis of rectal cancer were redefined as sigmoid cancer, with potential implications for multimodality treatment and prognostic value. Given the substantial interhospital variation in proportion of redefined cancers, the use of the STO will contribute to standardisation and comparability of outcomes in both daily practice and trial settings.